An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies

Ntumngia, Francis B.; Pires, Camilla Valente; Barnes, Samantha J.; George, Miriam T.; Thomson-Luque, Richard; Kano, Flora Satiko; Alves, Jessica Rafaela dos Santos; Urusova, Darya; Pereira, Dhelio Batista; Tolia, Niraj H.; King, Christopher L.; Carvalho, Luzia Helena de; Adams, John H..
Artículo en Inglés | ARCA | ID: arc-25302

Documentos relacionados

  1. Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.
  2. Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.
  3. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.
  4. Placental and colostral transfer of antibodies reactive with enteropathogenic Escherichia coli intimins a, ß, or gama
  5. Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.
  6. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.
  7. An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies.
  8. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.
  9. Multiplexed Microsphere-Based Flow Cytometric Assay to Assess Strain Transcending Antibodies to <i>Plasmodium vivax</i> Duffy Binding Protein II Reveals an Efficient Tool to Identify Binding-Inhibitory Antibody Responders.
  10. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.